Zimbabwe has rejected a major US healthcare agreement worth $367m (£272m) over five years due to Washington's insistence on confidential information.
The decision became public after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "skewed".
An official spokesperson has since explained that the US was requesting biological samples for research and commercial gain while refused to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for continued negotiations to find a deal agreeable to all parties so the nation's vital HIV programme can proceed.
Wider Implications
This development follows a comparable case in Kenya, where a high court blocked a similar deal with the US following concerns were filed about the security of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and accountability.
As per statements, Sixteen nations in Africa have to date signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our people if a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending frameworks already established through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is intended to ensure that when a country contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future co-operation might be designed in a way that honours the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body stated it acknowledged the government's concerns, but urged that talks need to persist since much of the country's Aids initiatives depended on international support.
"In cases where technical issues arise, such as those involving data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group commented.
The situation underscores the continuing tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more interconnected world.